Supplementary Figure S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

Nicolas Sayegh; Ryon P. Graf; Umang Swami; Zeynep İrem Özay; Chadi Hage Chehade; Julia Andrea Elvin; Douglas I. Lin; Júlia C.F. Quintanilha; Gerald Li; Alan Haruo Bryce; Rana R. McKay; Jeffrey S. Ross; Tian Zhang; Neeraj Agarwal

doi:10.1158/1078-0432.31353280

Supplementary Figure S2 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

2026 Open access

Read full text

Authors: Nicolas Sayegh, Ryon P. Graf, Umang Swami, Zeynep İrem Özay, Chadi Hage Chehade, Julia Andrea Elvin, Douglas I. Lin, Júlia C.F. Quintanilha, Gerald Li, Alan Haruo Bryce, Rana R. McKay, Jeffrey S. Ross

+2 more

Tian Zhang, Neeraj Agarwal

DOI: 10.1158/1078-0432.31353280

Cited by: 0

Abstract

Multivariable Outcomes by Biomarker Status on Chemo. Adjusting for potential known confounders, multivariable models evaluating (A) TTNT and (B) OS are shown.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Prostate Cancer Treatment and Research Cancer Genomics and Diagnostics

Publication details

Publication date: 17 February 2026
Language: EN